1. Pink Sheet
  2. >>Product Reviews

NZ Govt Moves To Speed Drug Access Amid Plans To Wipe Out Major New Act

 
• By Neena Brizmohun

A parallel assessment mechanism that will allow new medicines in any therapeutic area to be considered for funding sooner is being introduced in New Zealand, where the new coalition government is working to repeal last year’s landmark Therapeutic Products Act.

New Zealand's Parliament building in Wellington, NZ.
New Zealand's coalition government was formed last November • Source: Shutterstock

Streamlined assessments that New Zealand’s regulator and health technology assessment (HTA) body offer for cancer drugs are being expanded to cover medicines in all therapeutic areas, says the new coalition government, which plans to repeal the landmark Therapeutic Products Act (TPA) that was passed last year.

HTA body Pharmac is to assess funding applications for all new medicines that are still being evaluated for marketing authorization by the drugs regulator, Medsafe, so that products can be

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By Kate Rawson

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.

EU HTA Regulation: ‘Stepping Beyond’ JCAs May Be Needed For Very Rare Disease Drugs

 
• By Francesca Bruce

Cooperation between health technology assessment bodies across the EU will lead to a better joint clinical assessment process over time, but patients cannot afford a lengthy wait for improvements, speakers at a cell & gene therapy conference said.